Mohit Mathur

Dr. Mohit Mathur


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Emery HaleyEmery Haley
Emery Haley
FCFrank R. Cockerill
Frank R. Cockerill
RPRick L Pesano
Rick L Pesano
RFRichard Festa
Richard Festa
NLNatalie Luke
Natalie Luke
Natalie LukeNatalie Luke
Natalie Luke
Background/Objectives: While new methods for measuring antimicrobial susceptibility have been associated with improved patient outcomes, they should also be validated using standard protocols for error rates and other test metrics. The objective of this study was to validate a novel susceptibility assay for complicated and recurrent urinary tract infections (UTIs): pooled antibiotic susceptibility testing (P-AST). This assay was compared to broth microdilution (BMD) and disk diffusion (DD), following Clinical and Laboratory Standards Institute (CLSI) guidelines for assessment of error rates and agreement. Methods: This study analyzed consecutive fresh clinical urine specimens submitted for UTI diagnostic testing. Upon receipt, the urine samples were subjected in parallel to standard urine culture and multiplex polymerase chain reaction (M-PCR) for microbial identification and quantification. Specimens with the same monomicrobial non-fastidious bacteria detected by both M-PCR and standard urine culture (SUC) underwent standard antibiotic susceptibility testing (AST) and P-AST antibiotic susceptibility testing. Analysis was also undertaken to assess the presence of heteroresistance for specimens with P-AST-resistant and BMD/DD consensus-susceptible results. Results: The performance measures without correction for heteroresistance showed essential agreement (EA%) of ≥90%, very major errors (VMEs) of <1.5%, and major errors (MEs) of 88%), as the majority of the errors were minor (mEs) with essential agreement. The very major and major error rates for P-AST decreased to <1.0% when heteroresistance was accounted for. Conclusions: The P-AST assay methodology is validated within acceptable parameters when compared to broth microdilution and disk diffusion using CLSI criteria.

26 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Emery HaleyEmery Haley
Emery Haley
NLNatalie Luke
Natalie Luke
HKHoward Korman
Howard Korman
Natalie LukeNatalie Luke
Natalie Luke
DWDakun Wang
Dakun Wang
MMMohit Mathur
Mohit Mathur
This study compared rates of empirical-therapy use and negative patient outcomes between complicated and recurrent urinary tract infection (r/cUTI) cases diagnosed with a multiplex polymerase chain reaction or pooled antibiotic susceptibility testing (M-PCR/P-AST) vs. standard urine culture (SUC). Subjects were 577 symptomatic adults (n = 207 males and n = 370 females) presenting to urology/urogynecology clinics between 03/30/2022 and 05/24/2023. Treatment and outcomes were recorded by the clinician and patient surveys. The M-PCR/P-AST (n = 252) and SUC (n = 146) arms were compared after patient matching for confounding factors. The chi-square and Fisher’s exact tests were used to analyze demographics and clinical outcomes between study arms. Reduced empirical-treatment use (28.7% vs. 66.7%), lower composite negative events (34.5% vs. 46.6%, p = 0.018), and fewer individual negative outcomes of UTI-related medical provider visits and UTI-related visits for hospitalization/an urgent care center/an emergency room (p < 0.05) were observed in the M-PCR/P-AST arm compared with the SUC arm. A reduction in UTI symptom recurrence in patients ≥ 60 years old was observed in the M-PCR/P-AST arm (p < 0.05). Study results indicate that use of the M-PCR/P-AST test reduces empirical antibiotic treatment and negative patient outcomes in r/cUTI cases.

16 August 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
LPLaura K. S. Parnell
Laura K. S. Parnell
NLNatalie Luke
Natalie Luke
MMMohit Mathur
Mohit Mathur
RFRichard Festa
Richard Festa
Emery HaleyEmery Haley
Emery Haley
Natalie LukeNatalie Luke
Natalie Luke
The literature lacks consensus on the minimum microbial density required for diagnosing urinary tract infections (UTIs). This study categorized the microbial densities of urine specimens from symptomatic UTI patients aged ≥ 60 years and correlated them with detected levels of the immune response biomarkers neutrophil gelatinase-associated lipocalin (NGAL), interleukin-8 (IL-8), and interleukin-1-beta (IL-1β). The objective was to identify the microbial densities associated with significant elevation of these biomarkers in order to determine an optimal threshold for diagnosing symptomatic UTIs. Biobanked midstream voided urine samples were analyzed for microbial identification and quantification using standard urine culture (SUC) and multiplex-polymerase chain reaction (M-PCR) testing, while NGAL, IL-8, and IL-1β levels were measured via enzyme-linked immunosorbent assay (ELISA). NGAL, IL-8, and IL-1β levels were all significantly elevated at microbial densities ≥ 10,000 cells/mL when measured via M-PCR (p < 0.0069) or equivalent colony-forming units (CFUs)/mL via SUC (p < 0.0104) compared to samples with no detectable microbes. With both PCR and SUC, a consensus of two or more elevated biomarkers correlated well with microbial densities > 10,000 cells/mL or CFU/mL, respectively. The association between ≥10,000 cells and CFU per mL with elevated biomarkers in symptomatic patients suggests that this lower threshold may be more suitable than 100,000 CFU/mL for diagnosing UTIs.

1 May 2023 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
HKHoward J Korman
Howard J Korman
DBDavid Baunoch
David Baunoch
NLNatalie Luke
Natalie Luke
DWDakun Wang
Dakun Wang
XZXihua Zhao
Xihua Zhao
MMMohit Mathur
Mohit Mathur
Purpose: Complicated UTIs (cUTIs) cause significant morbidity and healthcare resource utilization and cost. Standard urine culture has limitations in detecting polymicrobial and non-E. coli infections, resulting in the under-diagnosis and under-treatment of cUTIs. In this study, patient-reported outcomes were compared between treated and untreated patients when an advanced diagnostic test combining multiplex-polymerase chain reaction (M-PCR) with a pooled antibiotic susceptibility method (P-AST) was incorporated into the patients’ clinical management. Methods: Patients who had symptoms typical of cUTI and positive M-PCR/P-AST test results were recruited from urology clinics. Symptom reduction and clinical cure rates were measured from day 0 through day 14 using the American English Acute Cystitis Symptom Score (ACSS) Questionnaire. Clinical cure was defined based on the sum of the scores of four US Food and Drug Administration (FDA) symptoms and the absence of visible blood in the urine. Results: Of 264 patients with suspected cUTI, 146 (55.4%) had exclusively non-E. coli infections (115 treated and 31 untreated) and 190 (72%) had polymicrobial infections (162 treated and 28 untreated). Treated patients exhibited greater symptom reduction compared to untreated ones on day 14 for those with exclusively non-E. coli organisms (3.18 vs 1.64, p = 0.006) and polymicrobial infections (3.52 vs 1.41, p = 0.002), respectively. A higher percentage of treated patients than of untreated patients achieved clinical cure for polymicrobial infections on day 14 (58.7% vs 36.4%, p = 0.049). Conclusion: Patients with cUTIs treated based on the M-PCR/P-AST diagnostic test had significantly improved symptom reduction and clinical cure rates compared to untreated patients among those with non-E. coli or polymicrobial infections.

1 May 2023 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
HKHoward J Korman
Howard J Korman
MMMohit Mathur
Mohit Mathur
NLNatalie Luke
Natalie Luke
DWDakun Wang
Dakun Wang
XZXihua Zhao
Xihua Zhao
DBDavid Baunoch
David Baunoch
Objective: To compare antibiotic resistance results at different time points in patients with urinary tract infections (UTIs), who were either treated based upon a combined multiplex polymerase chain reaction (M-PCR) and pooled antibiotic susceptibility test (P-AST) or were not treated. Methods: The M-PCR/P-AST test utilized here detects 30 UTI pathogens or group of pathogens, 32 antibiotic resistance (ABR) genes, and phenotypic susceptibility to 19 antibiotics. We compared the presence or absence of ABR genes and the number of resistant antibiotics, at baseline (Day 0) and 5– 28 days (Day 5– 28) after clinical management in the antibiotic-treated (n = 52) and untreated groups (n = 12). Results: Our results demonstrated that higher percentage of patients had a reduction in ABR gene detection in the treated compared to the untreated group (38.5% reduction vs 0%, p = 0.01). Similarly, significantly more patients had reduced numbers of resistant antibiotics, as measured by the phenotypic P-AST component of the test, in the treated than in the untreated group (42.3% reduction vs 8.3%, p = 0.04). Conclusion: Our results with both resistance gene and phenotypic antibiotic susceptibility results demonstrated that treatment based upon rapid and sensitive M-PCR/P-AST resulted in reduction rather than induction of antibiotic resistance in symptomatic patients with suspected complicated UTI (cUTI) in an urology setting, indicating this type of test is valuable in the management of these types of patients. Further studies of the causes of gene reduction, including elimination of ABR gene-carrying bacteria and loss of ABR gene(s), are warranted.

20 November 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
RFRichard Festa
Richard Festa
FCFrank R. Cockerill
Frank R. Cockerill
RPRick L Pesano
Rick L Pesano
Emery HaleyEmery Haley
Emery Haley
NLNatalie Luke
Natalie Luke
Natalie LukeNatalie Luke
Natalie Luke
Background: Here, we validate a unique and rapid susceptibility assay, Pooled Antibiotic Susceptibility Testing (P-AST), used for complicated, persistent, and recurrent urinary tract infections (UTIs), following Clinical and Laboratory Standards Institute (CLSI) protocols and performance metrics. Methods: P-AST™ was validated against the standard disk diffusion method with discrepancy resolution by the broth microdilution reference method. Performance was evaluated for five groups of non-fastidious uropathogenic organisms (Enterobacterales, Enterococci, Staphylococci, Pseudomonas aeruginosa, and Acinetobacter species) for up to 20 antibiotics, as clinically relevant per group. Fresh (144 monomicrobial and 49 polymicrobial) and frozen (78 monomicrobial and 7 polymicrobial) clinical urine specimens, as well as contrived specimens from pre-characterized frozen “challenge” isolates (52 monomicrobial and 37 polymicrobial), were included. Results: P-AST met CLSI target performance criteria of ≥90.0% categorical agreement, <3.0% very major error, 95.0% across all analysis groups. Across all monomicrobial analyses, there were no very major errors (VMEs), and two major errors (MEs). Across all polymicrobial analyses, there were three VMEs and two MEs. No organism–antibiotic pair analysis had more than a single VME or ME. Conclusions: P-AST, a component of the Guidance® UTI assay, demonstrates acceptable performance within the thresholds established by CLSI when compared against standard and reference methods for antibiotic susceptibility testing. Appropriate performance was established in both monomicrobial and polymicrobial specimens for five CLSI-defined groups of uropathogenic bacteria, against up to 20 antibiotics as clinically relevant to each organism group.